Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carrie Kitko

Pediatric Hematology-Oncology Nashville, TN Medical Doctor

NPI 1205912177 CMS profile 236231

3601 The Vanderbilt Clinic, Nashville, TN 37232

Open in the dashboard

General payments

$50,599

61 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$925,914 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Carrie Kitko of Nashville, TN is reported in the CMS Open Payments database as having received $50,599 across 61 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $925,914 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,843 18
2024 General $19,769 19
2023 General $7,436 14
2022 General $74 1
2021 General $4,755 2
2020 General $163 2
2019 General $559 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie Kitko
  • Pediatric Hematology-Oncology median
  • Middle half of Pediatric Hematology-Oncology
  • National median

In program year 2025, general payments to Carrie Kitko were reported at $17,843. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.

Show as a table
Year Carrie Kitko Pediatric Hematology-Oncology median Middle half National median
2019 $559 $184 $69–$2,094 $163
2020 $163 $220 $37–$3,941 $114
2021 $4,755 $366 $63–$4,909 $132
2022 $74 $181 $66–$2,775 $149
2023 $7,436 $175 $62–$2,600 $160
2024 $19,769 $227 $66–$2,992 $164
2025 $17,843 $204 $80–$2,819 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Incyte Corporation $16,407 22 payments
  2. Sanofi-Aventis U.S. LLC $12,824 6 payments
  3. CSL Behring $10,200 2 payments
  4. Horizon Therapeutics plc $4,650 1 payment
  5. Mesoblast, Inc. $3,125 1 payment
  6. Adaptive Biotechnologies Corporation $1,893 14 payments
  7. Novartis Pharmaceuticals Corporation $507 6 payments
  8. Jazz Pharmaceuticals Inc. $491 4 payments
  9. Kite Pharma, Inc. $187 2 payments
  10. Syndax Pharmaceuticals, Inc. $135 1 payment
  11. Other $179 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $37,937 8 payments
  2. Honoraria $4,650 1 payment
  3. Food and Beverage $3,044 37 payments
  4. Travel and Lodging $2,995 14 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,972 1 payment
Products named General payments · program years 2019–2025
  1. NIKTIMVO $7,566 7 payments
  2. ACTIMMUNE $4,650 1 payment
  3. Ryoncil $3,125 1 payment
  4. THYMOGLOBULIN $2,046 2 payments
  5. clonoSEQ $1,819 13 payments
  6. DEFITELIO Hematology $360 3 payments
  7. KYMRIAH $333 4 payments
  8. DEFITELIO Hematology/Oncology $131 1 payment
  9. JAKAFI $130 1 payment
  10. Yescarta $113 1 payment
  11. Other $450 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Hematology-Oncology: 604

Drug cost

$431,150

Median for Hematology-Oncology: $1,306,514

Branded share of claims

100%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rezurock Belumosudil Mesylate Brand 12 $431,150

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Records

61 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Hematology-Oncology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record